When Science Learns to Speak the Market's Language
There's a silent gap between what academia produces and what industry can actually use.
It's not a lack of scientific quality. Brazil produces excellent science — publications in high-impact international journals, researchers with decades of expertise, internationally validated methodologies. The problem is different: science, more often than not, was never trained to communicate with those who need it outside the university.
NexusBioTox's story begins exactly in that gap.
The realization that changes everything
Jerusa Maria de Oliveira Amorim spent more than 15 years building expertise in ecotoxicology, nanobiotechnology, and alternative models for toxicological assessment. During that time, she published in international journals, mentored students, served on animal ethics committees, and built the protocols that today form NexusBioTox's technical core.
The turning point did not come from a scientific discovery. It came from a conversation — the moment she realized that the bottleneck industries faced in developing new products was exactly the problem she already knew how to solve.
"I realized that what I was already doing daily in the lab could be exactly the solution that companies and other researchers were looking for," Jerusa says in the feature published by UFAL’s news portal in May 2026.
But realizing is not the same as knowing how to execute. Between that realization and the first paying client, there was an intense process of deconstruction — of language, of mindset, of how she presented her own work.
What academia does not teach
The scientific rigor that shapes good researchers — the need to prove before asserting, to document every variable, to contextualize every result within the literature — is exactly what makes scientific communication inaccessible to corporate decision-makers.
An R&D manager at a pharmaceutical company does not need to understand the difference between SOD and CAT. They need to know how long it will take, how much it will cost, and whether the data generated will be accepted by ANVISA (Brazil's health regulatory agency).
That translation — from methodology to business value — was the central lesson of the journey that led to NexusBioTox. And it does not happen naturally. It demands intention, market exposure, and the willingness to reshape your own message again and again.
What NexusBioTox delivers
The company works with preclinical toxicological assays using alternative models — zebrafish (Danio rerio), fruit fly (Drosophila melanogaster), and brine shrimp (Artemia salina) — which replace traditional mammalian testing with clear technical and ethical advantages.
In practice, this means:
Results in 6 to 7 months, versus years with traditional models. Up to 80% cost savings per compound. Data valid for regulatory submission to ANVISA, IBAMA, OECD, and REACH. Standardized protocols with scientific rigor and proven reproducibility. Reports that include technical interpretation and regulatory support.
Sectors served include pharmaceutical, agrochemical, cosmetic, environmental, and nanotechnology — any field that needs to prove a compound, formulation, or material is safe before moving into clinical or regulatory phases.
Science that goes beyond university walls
The UFAL feature — available in full at the link below — documents not just what NexusBioTox does, but how it got here: through academic partnership, university infrastructure, validation via innovation programs, and a multidisciplinary team that keeps the company connected to the frontier of knowledge.
For us, this recognition matters less as a trophy and more as a record: proof that it is possible to build serious science and a real business at the same time, without giving up either one.
🔗 Read the full article: noticias.ufal.br
📩 Get to know NexusBioTox: nexusbiotox.com.br
